COMPASS Pathways plc (NASDAQ:CMPS) Receives Consensus Rating of “Buy” from Analysts

Shares of COMPASS Pathways plc (NASDAQ:CMPS) have received a consensus recommendation of “Buy” from the six ratings firms that are covering the firm, Marketbeat Ratings reports. Six equities research analysts have rated the stock with a buy recommendation. The average 12 month price objective among brokers that have updated their coverage on the stock in the last year is $33.60.

A number of research analysts have recently commented on the company. Royal Bank of Canada reiterated an “outperform” rating and issued a $18.00 price objective on shares of COMPASS Pathways in a report on Wednesday, January 15th. HC Wainwright reduced their price objective on shares of COMPASS Pathways from $120.00 to $60.00 and set a “buy” rating for the company in a research report on Friday, November 1st. Finally, Maxim Group dropped their target price on shares of COMPASS Pathways from $22.00 to $12.00 and set a “buy” rating on the stock in a research report on Friday, November 1st.

COMPASS Pathways Stock Performance

Shares of CMPS stock opened at $4.41 on Friday. COMPASS Pathways has a 12 month low of $3.16 and a 12 month high of $12.75. The company has a current ratio of 8.91, a quick ratio of 8.91 and a debt-to-equity ratio of 0.15. The company has a market cap of $301.74 million, a P/E ratio of -2.00 and a beta of 2.28. The firm has a fifty day moving average price of $4.10 and a 200 day moving average price of $5.59.

Hedge Funds Weigh In On COMPASS Pathways

Institutional investors have recently modified their holdings of the business. Polar Asset Management Partners Inc. grew its position in COMPASS Pathways by 83.3% during the 3rd quarter. Polar Asset Management Partners Inc. now owns 567,600 shares of the company’s stock worth $3,576,000 after purchasing an additional 258,000 shares during the last quarter. Sio Capital Management LLC increased its position in COMPASS Pathways by 211.7% in the 3rd quarter. Sio Capital Management LLC now owns 914,639 shares of the company’s stock valued at $5,762,000 after acquiring an additional 621,222 shares during the period. Walleye Capital LLC purchased a new stake in COMPASS Pathways during the 3rd quarter valued at approximately $2,126,000. Acuta Capital Partners LLC acquired a new stake in COMPASS Pathways during the 3rd quarter worth approximately $2,435,000. Finally, Geode Capital Management LLC grew its stake in shares of COMPASS Pathways by 160.3% in the 3rd quarter. Geode Capital Management LLC now owns 42,169 shares of the company’s stock valued at $266,000 after purchasing an additional 25,970 shares during the last quarter. 46.19% of the stock is owned by institutional investors and hedge funds.

About COMPASS Pathways

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.